Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 52,600 shares, an increase of 19.0% from the October 31st total of 44,200 shares. Based on an average daily trading volume, of 64,200 shares, the short-interest ratio is presently 0.8 days.

Entera Bio Price Performance

NASDAQ ENTX opened at $1.68 on Tuesday. Entera Bio has a 1-year low of $0.52 and a 1-year high of $3.35. The business has a 50 day simple moving average of $1.79 and a two-hundred day simple moving average of $1.86. The stock has a market capitalization of $60.11 million, a PE ratio of -6.31 and a beta of 1.58.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Entera Bio in a research report on Monday, November 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in Entera Bio during the first quarter valued at $37,000. Signature Estate & Investment Advisors LLC bought a new position in shares of Entera Bio in the 3rd quarter valued at about $90,000. Finally, Parkman Healthcare Partners LLC grew its position in Entera Bio by 2.4% in the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after acquiring an additional 9,558 shares in the last quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.